LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link

Three prominent in-house counsel foretell the risks and opportunities in the pharma, data privacy and e-commerce sectors


Shantanu-Mukherjee-is-legal-head,-Asia-Pacific-and-Japan-at-Lupin.
SHANTANU MUKHERJEE

Pharma: evolving priorities

The year ahead will see pharma companies and their general counsel (GC) continue to grapple with the demands of the volatile, uncertain, complex and ambiguous (VUCA) business environment they find themselves in. The global marketplace that Indian pharma companies operate in today is far more challenging than it was a decade ago. Companies must navigate a complex maze of interconnected risks – political, macro-economic, technological, tax, financial, legal, regulatory – that run across political borders. A tweet can disrupt a strategy, an alliance between your customers can halve your margins, and regulatory changes can open or close entire markets.

In this VUCA world, an in-house counsel must anticipate, mitigate and live with all kinds of risk, and bring more than mere legal expertise to the table – one must also be a dealmaker, reformer, crisis manager and strategist.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们

ESHA CHAKRAVARTY is general manager-legal at Datamatics Business Solutions.

LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link